{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:12:04Z","timestamp":1790932324094,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.soc.2022.03.006","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T23:19:24Z","timestamp":1655248764000},"page":"419-430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Management of Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma"],"prefix":"10.1016","volume":"31","author":[{"given":"Aimee M.","family":"Crago","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Kose\u0142a-Paterczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.soc.2022.03.006_bib1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/PAS.0000000000000564","article-title":"Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST","volume":"40","author":"Prieto-Granada","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.soc.2022.03.006_bib2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/PAT.0000000000000122","article-title":"STAT6 rabbit monoclonal antibody is a robust diagnostic tool for the distinction of solitary fibrous tumour from its mimics","volume":"46","author":"Cheah","year":"2014","journal-title":"Pathology"},{"issue":"3","key":"10.1016\/j.soc.2022.03.006_bib3","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/modpathol.2013.164","article-title":"Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics","volume":"27","author":"Doyle","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.soc.2022.03.006_bib4","series-title":"WHO classification of Tumours of soft tissue and bone","first-page":"195","author":"Dry","year":"2020"},{"issue":"4","key":"10.1016\/j.soc.2022.03.006_bib5","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","article-title":"Electronic address edsc, Cancer Genome Atlas Research N. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas","volume":"171","year":"2017","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.soc.2022.03.006_bib6","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ng.619","article-title":"Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy","volume":"42","author":"Barretina","year":"2010","journal-title":"Nat Genet"},{"issue":"22","key":"10.1016\/j.soc.2022.03.006_bib7","first-page":"6339","article-title":"The RB1 gene is the target of chromosome 13 deletions in malignant fibrous histiocytoma","volume":"60","author":"Chibon","year":"2000","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.soc.2022.03.006_bib8","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.2353\/ajpath.2010.100104","article-title":"Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics","volume":"177","author":"Perot","year":"2010","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.soc.2022.03.006_bib9","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/00000478-199604000-00001","article-title":"Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant","volume":"20","author":"Mentzel","year":"1996","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.soc.2022.03.006_bib10","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1245\/s10434-015-5063-5","article-title":"Optimal Percent Myxoid Component to Predict Outcome in High-Grade Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma","volume":"23","author":"Lee","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.soc.2022.03.006_bib11","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1200\/JCO.2001.19.12.3045","article-title":"Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification","volume":"19","author":"Fletcher","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.soc.2022.03.006_bib12","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/(SICI)1097-0142(19990415)85:8<1765::AID-CNCR17>3.0.CO;2-K","article-title":"Malignant fibrous histiocytoma of the extremity","volume":"85","author":"Salo","year":"1999","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.soc.2022.03.006_bib13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ijrobp.2018.05.055","article-title":"Localized Myxofibrosarcomas: Roles of Surgical Margins and Adjuvant Radiation Therapy","volume":"102","author":"Boughzala-Bennadji","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.soc.2022.03.006_bib14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1245\/s10434-012-2572-3","article-title":"Prognostic factors and outcomes of patients with myxofibrosarcoma","volume":"20","author":"Look Hong","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.soc.2022.03.006_bib15","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1245\/s10434-010-1341-4","article-title":"Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution","volume":"18","author":"Sanfilippo","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.soc.2022.03.006_bib16","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/cncr.26296","article-title":"The enigma of myxofibrosarcoma of the extremity","volume":"118","author":"Mutter","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.soc.2022.03.006_bib17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ijrobp.2010.08.042","article-title":"Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma","volume":"82","author":"Haglund","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.soc.2022.03.006_bib18","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00256-012-1563-6","article-title":"Myxofibrosarcoma: prevalence and diagnostic value of the \"tail sign\" on magnetic resonance imaging","volume":"42","author":"Lefkowitz","year":"2013","journal-title":"Skeletal Radiol"},{"issue":"2","key":"10.1016\/j.soc.2022.03.006_bib19","doi-asserted-by":"crossref","first-page":"W193","DOI":"10.2214\/AJR.05.1130","article-title":"Low-grade myxofibrosarcoma: CT and MRI patterns in recurrent disease","volume":"188","author":"Waters","year":"2007","journal-title":"AJR Am J roentgenology"},{"key":"10.1016\/j.soc.2022.03.006_bib20","article-title":"Temporizing Wound VAC Dressing Until Final Negative Margins are Achieved Reduces Myxofibrosarcoma Local Recurrence","author":"Fourman","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.soc.2022.03.006_bib21","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/SLA.0b013e318155a9ae","article-title":"Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas","volume":"246","author":"Pisters","year":"2007","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.soc.2022.03.006_bib22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/SLA.0b013e3182367aa7","article-title":"A\u00a0postoperative nomogram for local recurrence risk in extremity soft tissue sarcomas after limb-sparing surgery without adjuvant radiation","volume":"255","author":"Cahlon","year":"2012","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.soc.2022.03.006_bib23","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/cncr.23592","article-title":"A\u00a0systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma","volume":"113","author":"Pervaiz","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.soc.2022.03.006_bib24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejca.2018.12.009","article-title":"The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial","volume":"109","author":"Pasquali","year":"2019","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.soc.2022.03.006_bib25","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(16)00010-3","article-title":"Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis","volume":"17","author":"Callegaro","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.soc.2022.03.006_bib26","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S1470-2045(17)30334-0","article-title":"Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial","volume":"18","author":"Gronchi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.soc.2022.03.006_bib27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/cncr.33895","article-title":"Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial","volume":"128","author":"Pasquali","year":"2022","journal-title":"Cancer"},{"issue":"Suppl 4","key":"10.1016\/j.soc.2022.03.006_bib28","doi-asserted-by":"crossref","first-page":"iv51","DOI":"10.1093\/annonc\/mdy096","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.soc.2022.03.006_bib29","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.soc.2022.03.006_bib30","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1200\/JCO.2006.10.4117","article-title":"Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002","volume":"25","author":"Maki","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.soc.2022.03.006_bib31","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","article-title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial","volume":"18","author":"Seddon","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9829","key":"10.1016\/j.soc.2022.03.006_bib32","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.soc.2022.03.006_bib33","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.soc.2022.03.006_bib34","doi-asserted-by":"crossref","first-page":"11015","DOI":"10.1200\/JCO.2019.37.15_suppl.11015","article-title":"Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated\/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts","volume":"37","author":"Burgess","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.soc.2022.03.006_bib35","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D'Angelo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.soc.2022.03.006_bib36","doi-asserted-by":"crossref","first-page":"11505","DOI":"10.1200\/JCO.2020.38.15_suppl.11505","article-title":"Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS)","volume":"38","author":"Roland","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.soc.2022.03.006_bib37","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1158\/2159-8290.CD-15-1481","article-title":"Integrin-alpha10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma","volume":"6","author":"Okada","year":"2016","journal-title":"Cancer Discov"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320722000199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320722000199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:05:29Z","timestamp":1760961929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320722000199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1055320722000199"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2022.03.006","relation":{},"ISSN":["1055-3207"],"issn-type":[{"value":"1055-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2022.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}